Retail Offer

CRISM Therapeutics Corporation (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") of nil par value each in the capital of the Company (the "Retail Offer Shares") at an issue price of 9 pence per Retail Offer Share (the "Issue Price") to raise up to £100,000.

In addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares (the "Placing Shares" and together with the Retail Offer Shares, the "New Ordinary Shares") at the Issue Price (the "Placing" and together with the Retail Offer, the "Issue"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing.

The Retail Offer is conditional on the New Ordinary Shares to be issued pursuant to the Retail Offer being admitted to trading on the AIM market operated by the London Stock Exchange ("Admission"). Admission of the New Ordinary Shares pursuant to the Retail Offer is expected to take place at 16 December 2025. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.

The net proceeds from the Retail Offer and the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.

Investor Meet Company Presentation

Andrew Webb, CEO of CRISM Therapeutics, will host a live presentation and Q&A in connection with the Retail Offer via Investor Meet Company on Thursday 11 December 2025 at 12.00pm GMT.

Investors can sign up, free of charge, to Investor Meet Company and add to meet CRISM Therapeutics via: https://www.investormeetcompany.com/crism-therapeutics-corporation/register

Expected Timetable in relation to the Retail Offer

Retail Offer

The Company values its retail shareholder base. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/2Q39JQ/authorised-intermediaries

SP Angel Corporate Finance LLP will be acting as retail offer coordinator in relation to this Retail Offer (the "Retail Offer Coordinator").

The Retail Offer will be open to eligible investors in the United Kingdom at 7:30am on 10/12/2025. The Retail Offer is expected to close at 12:00pm on 15/12/2025. Investors should note that financial intermediaries may have earlier closing times. The Retail Offer may close early if it is oversubscribed.

The Retail Offer the subject of this announcement is and will, at all times, only be made to, directed at and may only be acted upon by those persons who are, shareholders in the Company. To be eligible to participate in the Retail Offer, applicants must meet the following criteria before they can submit an order for Retail Offer Shares: (i) be a customer of one of the participating intermediaries listed on the above website; (ii) be resident in the United Kingdom and (iii) be a shareholder in the Company (which may include individuals aged 18 years or over, companies and other bodies corporate, partnerships, trusts, associations and other unincorporated organisations and includes persons who hold their shares in the Company directly or indirectly through a participating intermediary).

There is a minimum subscription of £100.00 per investor under the terms of the Retail Offer which is open to investors in the United Kingdom subscribing via the intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/2Q39JQ/authorised-intermediaries

The Company's LEI is 213800XFW6MKVCHHPW88.

UK Product Governance Requirements

EU Product Governance Requirements